Evidence map›Paper›PMID 37931176›Full record

ArticleThe neuroradiology journal2024

Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma.

Michael Iv, Lewis Naya, Sajal Sanan, Samuel L Van Buskirk, Seema Nagpal, Reena P Thomas, Lawrence D Recht, Chirag B Patel

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The neuroradiology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The therapeutic efficacy and application prospects of tumor-treating fields (TTFields) in resolving malignant tumors of central nervous system.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  5. Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  6. Article
  7. Tumor-treating fields in cancer therapy: advances of cellular and molecular mechanisms.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Michael IvDivision of Neuroradiology, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Lewis NayaStanford Cancer Institute, Stanford, CA, USA.
Sajal SananSchool of Medicine, University of Washington, Seattle, WA, USA.
Samuel L Van BuskirkDepartment of Psychology, University of Texas at San Antonio, San Antonio, TX, USA.
Seema NagpalDivision of Neuro-Oncology, Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
Reena P ThomasDivision of Neuro-Oncology, Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
Lawrence D RechtDivision of Neuro-Oncology, Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
Chirag B PatelDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0787-0634
Stanford University · USCancer Prevention Institute of California · USThe University of Texas at San Antonio · USThe University of Texas MD Anderson Cancer Center · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objective200 kHz tumor treating fields (TTFields) is clinically approved for newly-diagnosed glioblastoma (nGBM). Because its effects on conventional surveillance MRI brain scans are equivocal, we investigated its effects on perfusion MRI (pMRI) brain scans.

methodsEach patient underwent institutional standard pMRI: dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) pMRI at three time points: baseline, 2-, and 6-months on-adjuvant therapy. At each timepoint, the difference between T1 pre- versus post-contrast tumor volume (ΔT1) and these pMRI metrics were evaluated: normalized and standardized relative cerebral blood volume (nRCBV, sRCBV); fractional plasma volume (V

resultsAmong 13 pMRI datasets (11 nGBM, 2 recurrent GBM), therapies included temozolomide-only (

conclusionUsing pMRI, we provide initial in-human validation of pre-clinical studies regarding the effects of TTFields on tumor blood volume and BBB permeability in GBM.

Indexed as

Brain NeoplasmsGlioblastomaBlood-Brain BarrierCerebral Blood VolumeContrast MediaHumansMagnetic Resonance ImagingReproducibility of ResultsTemozolomideContrast MediaTemozolomideblood-brain barrierglioblastomamagnetic resonance imagingneuroimagingneuro-oncologyperfusion imagingpermeabilitytumor treating fields

Identifiers

PMID37931176
PMCPMC10863570
OpenAlexW4388406586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.